Yann Le Cam

3.1k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Yann Le Cam is a scholar working on Genetics, Economics and Econometrics and Immunology. According to data from OpenAlex, Yann Le Cam has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 13 papers in Economics and Econometrics and 5 papers in Immunology. Recurrent topics in Yann Le Cam's work include Genomics and Rare Diseases (14 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (5 papers). Yann Le Cam is often cited by papers focused on Genomics and Rare Diseases (14 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (5 papers). Yann Le Cam collaborates with scholars based in France, United Kingdom and United States. Yann Le Cam's co-authors include Ana Rath, Valérie Serrière-Lanneau, Daniel N. Murphy, Annie Olry, Deborah M. Lambert, Stéphanie Nguengang Wakap, Charlotte Rodwell, Maria Mavris, Monique Jeanblanc and Anneliene Hechtelt Jonker and has published in prestigious journals such as Nature Reviews Drug Discovery, Clinical Pharmacology & Therapeutics and Frontiers in Pharmacology.

In The Last Decade

Yann Le Cam

25 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database

2019 833 citations Stéphanie Nguengang Wakap, Deborah M. Lambert et al. European Journal of Human Genetics profile →

Peers

Countries citing papers authored by Yann Le Cam

Since Specialization

Citations

This map shows the geographic impact of Yann Le Cam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Le Cam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Le Cam more than expected).

Fields of papers citing papers by Yann Le Cam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Le Cam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Le Cam. The network helps show where Yann Le Cam may publish in the future.

Co-authorship network of co-authors of Yann Le Cam

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Le Cam. A scholar is included among the top collaborators of Yann Le Cam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Le Cam. Yann Le Cam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Strengthening health systems for access to gene therapy in rare genetic disorders 2024 ·Molecular Therapy — Methods & Clinical Development ·(unknown), Yann Le Cam, Juan Blanco, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Martin Schulz, Durhane Wong‐Rieger, (unknown)	2
2	Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey 2024 ·European Journal of Human Genetics ·(unknown), Claudia Crocione, (unknown), (unknown), (unknown), Amy Hunter, Lene Arnett Jensen, Cor Oosterwijk, (unknown), (unknown), Laurence Faivre, Michael Wilbur, Yann Le Cam, (unknown)	34
3	Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases 2024 ·Orphanet Journal of Rare Diseases ·Chiuhui Mary Wang, (unknown), Ana Rath, (unknown), Diego Ardigò, Gareth Baynam, Hugh Dawkins, Ada Hamosh, Yann Le Cam, Helen Malherbe, Caron Molster, Lucía Monaco, Carmencita D. Padilla, Anne Pariser, Peter N. Robinson, Charlotte Rodwell, Franz Schaefer, Stefanie Weber, (unknown)	6
4	Framing the European Rare Diseases field through a structured movement of patient organisations 2024 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), Virginie Hivert, (unknown), Yann Le Cam	2
5	Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA 2023 ·Orphanet Journal of Rare Diseases ·(unknown), (unknown), (unknown), Marc Van de Casteele, (unknown), (unknown), J. Pontén, Hans‐Georg Eichler, Yann Le Cam, (unknown), Anna Bucsics	8
6	Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group) 2021 ·Frontiers in Pharmacology ·Annemieke Aartsma‐Rus, Marc Dooms, Yann Le Cam	31
7	Our greatest untapped resource: our patients 2021 ·Journal of Community Genetics ·(unknown), Thomas Kenny, Yann Le Cam, (unknown)	11
8	Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database breakdown → 2019 ·European Journal of Human Genetics ·Stéphanie Nguengang Wakap, Deborah M. Lambert, Annie Olry, Charlotte Rodwell, (unknown), Valérie Serrière-Lanneau, Daniel N. Murphy, Yann Le Cam, Ana Rath	833
9	The evolution of adaptiveness: balancing speed and evidence 2018 ·Nature Reviews Drug Discovery ·Hans‐Georg Eichler, Richard Barker, (unknown), Jacoline C. Bouvy, André W. Broekmans, Anna Bucsics, Francesca Cerreta, Solange Corriol‐Rohou, Alı́cia Granados, Yann Le Cam, Ad Schuurman	6
10	Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? 2018 ·Clinical Pharmacology & Therapeutics ·Hans‐Georg Eichler, (unknown), Mathieu Boudes, Jacoline C. Bouvy, André W. Broekmans, Francesca Cerreta, Stuart Faulkner, (unknown), (unknown), Yann Le Cam, (unknown), (unknown), Solange Corriol‐Rohou	7
11	Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) 2017 ·Orphanet Journal of Rare Diseases ·Lieven Annemans, Ségolène Aymé, Yann Le Cam, Karen Facey, (unknown), Elena Nicod, Michele Reni, (unknown), Michael Schlander, David Taylor, Carlo Tomino, Josep Torrent-Farnell, Sheela Upadhyaya, Adam Hutchings, (unknown)	76
12	EURORDIS-Rare Diseases Europe 2017 ·Impact ·Yann Le Cam	17
13	The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact 2017 ·European Journal of Human Genetics ·Hanns Lochmüller, (unknown), Yann Le Cam, Anneliene Hechtelt Jonker, Lilian Pek Lian Lau, Gareth Baynam, Petra Kaufmann, Hugh Dawkins, Paul Lasko, Christopher P. Austin, Kym M. Boycott	59
14	Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective 2017 ·Clinical and Translational Science ·Hugh Dawkins, Ruxandra Draghia‐Akli, Paul Lasko, Lilian Pek Lian Lau, Anneliene Hechtelt Jonker, Christine M. Cutillo, Ana Rath, Kym M. Boycott, Gareth Baynam, Hanns Lochmüller, Petra Kaufmann, Yann Le Cam, Virginie Hivert, Christopher P. Austin	100
15	‘IRDiRC Recognized Resources’: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases 2016 ·European Journal of Human Genetics ·Hanns Lochmüller, Yann Le Cam, Anneliene Hechtelt Jonker, Lilian Pek Lian Lau, Gareth Baynam, Petra Kaufmann, Paul Lasko, Hugh Dawkins, Christopher P. Austin, Kym M. Boycott	26
16	The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks 2016 ·Orphanet Journal of Rare Diseases ·Teresinha Evangelista, (unknown), António Atalaia, Matt Johnson, Stephen Lynn, Yann Le Cam, Kate Bushby	25
17	Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives 2014 ·Orphanet Journal of Rare Diseases ·(unknown), (unknown), Yann Le Cam, Sarah Garner, Emmanuelle Voisin, (unknown), (unknown), M. Slaoui	8
18	EUROPLAN: A Project to Support the Development of National Plans on Rare Diseases in Europe 2013 ·Public Health Genomics ·Domenica Taruscio, (unknown), Marta De Santis, Rita Maria Ferrelli, Manuel Posada de la Paz, (unknown), (unknown), Laura Fregonese, Румен Стефанов, (unknown), (unknown), Yann Le Cam, Desirée Gavhed, Pierpaolo Mincarone, Kate Bushby, (unknown), (unknown), Luciano Vittozzi, (unknown)	10
19	Involvement of Patient Organisations in Research and Development of Orphan Drugs for Rare Diseases in Europe 2012 ·Molecular Syndromology ·Maria Mavris, Yann Le Cam	48
20	Progressive enlargement of filtrations with initial times 2009 ·Stochastic Processes and their Applications ·Monique Jeanblanc, Yann Le Cam	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact